Trump Tariffs make Medicine, Trucks and Furniture More Expensive

When Donald Trump says “America First,” everyone else had better strap on a helmet. His latest move is a trade blitz that imposes 100% tariffs on branded and patented pharmaceuticals, as well as hefty duties on trucks, furniture, and cabinets, all effective October 1, 2025. The president framed it as protecting U.S. jobs and national security, but for consumers and global partners, it looks more like a costly gamble. As one trade analyst quipped, “The cure is looking more expensive than the disease.” Trump insists it’s about protecting U.S. industry and jobs. Critics argue it’s a recipe for higher prices, global retaliation, and fresh uncertainty in industries already grappling with supply chain headaches. Let’s break down the fallout, sector by sector.

Pharma Gets a Pricey Prescription

The biggest headline is Trump’s 100% tariff on branded drugs, unless companies are actively building plants in the U.S. “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump posted on Truth Social.

• Winners: U.S.-based producers like Johnson & Johnson and Eli Lilly, both of which are investing billions in new U.S. facilities.
• Losers: Global pharma giants like Novo Nordisk, AstraZeneca, and Novartis, which still rely heavily on exports to America. Novo Nordisk’s shares slid 3.5% the day after the announcement.

The exemption for generics, which account for about 90% of U.S. prescriptions, means that everyday drugs may escape the hit. But speciality treatments like cancer or rare disease therapies could skyrocket. An EY study found that even a 25% tariff on patented drugs could add $51 billion a year to U.S. drug costs. Imagine what 100% could do. The European Union negotiated a 15% tariff ceiling earlier this year, shielding most of its exports. But the U.K. and Switzerland aren’t covered. That leaves their $6.5 billion in U.K. pharma exports and Switzerland’s biotech blockbusters staring down Trump’s full penalty.

Trucking into Trouble

Next on the list: a 25% tariff on heavy-duty trucks. Trump says it’s about protecting Peterbilt, Kenworth, Freightliner, and Mack Trucks from “unfair outside competition.” Here’s the kicker: most imports come from allies like Mexico, Canada, Japan, Germany, and Finland. The U.S. Chamber of Commerce called the move unnecessary, pointing out that Mexico already supplies 95% of U.S. tractor-truck imports, with engines and parts that are often made in America anyway. Economists warn these tariffs could raise transportation costs, driving up the price of goods from groceries to construction materials. As UCLA’s Kimberly Clausing put it: “It just seems like a bizarre series of moves from an administration that was put in office in part to lower prices for households.”

Your Couch Just Got More Expensive

If you’ve been saving for that dream sectional or a kitchen redo, hold tight. Trump slapped 50% tariffs on kitchen and bathroom cabinets and 30% tariffs on upholstered furniture. The reason? He claims a “flooding” of imports from countries like Vietnam and China is drowning U.S. manufacturers. But the reality is that 60% of furniture sold in the U.S. comes from Asia, with some categories like wood furniture hitting 86%. Furniture prices were already up 4.7% last year, and dining/living room pieces jumped nearly 10%. IKEA says it’s “closely monitoring” the situation, but let’s be real, consumers are the ones likely to bear the cost.

Retaliation Watch

Trade wars aren’t one-way streets. Expect responses:

• EU: Already secured a cap but warned against U.S. “backsliding.”
• India: A top supplier of generics worth $10.5B to the U.S., may rethink cooperation if specialty medicines get squeezed.
• U.K. & Switzerland: Already crying foul, pushing Washington for exemptions.
• China: Likely to counterpunch, possibly targeting U.S. consumer goods or agriculture.

As we noted in Decoding Trump’s Tariff Map and Global Blowback, tariffs rarely stop at U.S. borders. They almost always invite retaliation, reshaping supply chains and rattling alliances. With healthcare now in the mix, the stakes for a blowback are even higher.

A Ghost That Won’t Quit

Tariffs might sound like a tax on foreign companies, but in reality, they act like a hidden tax on American households. Importers pay first, and those costs trickle down to consumers in the form of higher prices. Treasury Secretary Scott Bessent has said the government could pull in $300 billion in tariff revenue this year, but that “win” for Washington means everyday Americans will feel the squeeze at pharmacies, in grocery aisles, and even at the furniture store. The pain won’t be limited to drug counters. A 25% tariff on heavy trucks could raise shipping costs, pushing up the price of groceries and construction materials. Furniture, already more expensive, with living room sets up nearly 10% last year, is set to climb higher. And on the healthcare side, insurers may pass rising drug costs into premiums, even for patients who don’t use those speciality medicines.

Markets have already factored in the risks. U.S. indexes dipped after the announcement, and pharma shares abroad slid, signalling investor concern that these tariffs could add fresh inflationary pressure just as the Fed tries to cool things down.

Winners and Losers

Hurt most:

• Global pharma exporters like Novartis, Sanofi, AstraZeneca, and Indian specialty drugmakers.
• Truck producers in Mexico and Canada.
• Furniture exporters across Asia.
• U.S. patients and households are facing higher prices.

Benefiting:

• U.S. pharma companies are already investing locally (Eli Lilly, J&J, Merck).
• Domestic truck and furniture makers, however, may see demand falter.
• Politicians running on the “Made in America” ticket.

The Takeaway

Trump’s new tariff cocktail is part economic strategy, part political theatre. It may help nudge some manufacturing back home, but the immediate reality looks like higher costs for consumers, market volatility, and global friction. And with healthcare and inflation already sore spots, the irony is hard to miss: in trying to make America healthier and wealthier, these tariffs may just leave patients and pockets worse off. Or as Wall Street might put it: the cure is looking more expensive than the disease. It also echoes what we explored in What Really Happened After Trump’s Tariffs, when a pause in duties briefly calmed markets before fresh tensions reignited. The pattern remains the same: tariffs may start as economic leverage, but they end up spilling into politics, markets, and household budgets.